Skip to main content
Clinical Trials/NCT05018091
NCT05018091CompletedPhase 4

Dexamethasone in Total Knee Arthroplasty: What Dose Should we be Giving Patients Intraoperatively

Rush University Medical Center10 sites in 1 country438 target enrollmentStarted: October 28, 2021Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
438
Locations
10
Primary Endpoint
Opioid Consumption

Study Overview

Brief Summary

The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.

Detailed Description

Study design: Prospective randomized controlled trial

Scientific Background: In contemporary total joint arthroplasty (TJA), multimodal anesthesia and analgesia is used to improve postoperative pain, reduce opioid consumption, and minimize complications after surgery such as postoperative nausea and vomiting.1-3 Multiple medications with varying mechanisms of action are used at different time points throughout the perioperative period to modulate different pain receptors. Corticosteroids are a medication commonly utilized intraoperatively as part of contemporary multimodal protocols.

Corticosteroids are frequently used in TJA due to their potent anti-inflammatory and anti-emetic properties. Several studies have demonstrated that corticosteroids reduce postoperative nausea and vomiting as well as postoperative pain and opioid consumption.4-6 However, the optimal medication, dose, and number of doses of corticosteroid that should be administered in the perioperative period remain unknown. In addition, it remains unclear if corticosteroids can be safely used in patients with diabetes mellitus or if corticosteroids increase the risk of postoperative complications such as periprosthetic joint infection. Thus, the purpose of our study is to determine the most efficacious and safest dose of corticosteroids that should be administered intraoperatively during TJA.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Age > 18 years
  • •Primary total knee arthroplasty
  • •Patients staying at least one night in the hospital after surgery

Exclusion Criteria

  • •Same day discharge Age < 18 years Revision or partial total knee arthroplasty Corticosteroid use within 3 months prior to surgery Inflammatory arthritis Current systemic fungal infection Renal or liver failure Prior adverse reaction to corticosteroid Primary TKA requiring hardware removal

Arms & Interventions

Group 1

Active Comparator

4mg intravenous dexamethasone, administered shortly after induction of anesthesia

Intervention: Dexamethasone 4mg (Drug)

Group 2

Active Comparator

8mg intravenous dexamethasone, administered shortly after induction of anesthesia

Intervention: Dexamethasone 8 Mg/mL Injectable Suspension (Drug)

Group 3

Active Comparator

16mg intravenous dexamethasone, administered shortly after induction of anesthesia

Intervention: Dexamethasone 16mg (Drug)

Outcomes

Primary Outcomes

Opioid Consumption

Time Frame: 48-hours postoperative (after surgical intervention)

48 hours of cumulative opioid consumption measured in oral morphine equivalents

Secondary Outcomes

  • Postoperative Pain Scores at Rest(assessed at days 1 through 7 after surgery, Day 7 reported)
  • Postoperative Nausea(assessed at days 1 through 7 after surgery, Day 7 reported)
  • Postoperative Blood Glucose Levels Without Diabetes(Glucose levels taken the morning after surgery)
  • Postoperative Blood Glucose Levels With Diabetes(Glucose levels taken the morning after surgery)
  • Number of Hours Slept Post Op Day 1(Post op day 1, recording of hours slept)
  • Number of Hours Slept Post Op Day 2(Post op day 2, hours slept)
  • Number of Hours Slept Post Op Day 3(Post op day 3, hours slept)
  • Number of Hours Slept Post Op Day 4(Hours slept on POD 4)
  • Number of Hours Slept Post Op Day 5(Hours slept on POD 5)
  • Number of Hours Slept Post Op Day 6(Hours slept on POD 6)
  • Number of Hours Slept Post Op Day 7(Hours slept on POD 7)
  • Number of Participants With Complications up to 30 Days After Surgical Intervention(<30 days after surgical intervention, document any readmissions to the hospital or complications that occur within 30 days from the day of surgery)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Craig J Della Valle, MD

Professor of Orthopedic Surgery, Chief Division of Adult Reconstruction

Rush University Medical Center

Study Sites (10)

Loading locations...

Similar Trials